Novavax coronavirus vaccine found 89 percent efficient in trials

Health.



29 January2021

By New Scientist
and Press Association

A scientist dealing with vaccine advancement at the Novavax laboratory in Gaithersburg, Maryland

ANDREW CABALLERO-REYNOLDS/AFP via Getty Images

A coronavirus vaccine developed by the United States firm Novavax has actually been shown to be 89 percent effective in preventing covid-19 in stage III clinical trials.

The vaccine is made from nanoparticles consisting of spike proteins from the virus, which are produced by genetically customized insect cells. The nanoparticles can not replicate or cause covid-19, but they enable the body’s body immune system to acknowledge the viral proteins and make antibodies against them.

The vaccine is provided as 2 dosages, but unlike the Pfizer/BioNTech …

Existing subscribers, please log in with your email address to connect your account gain access to.

Paid every year by Charge card

Inclusive of suitable taxes (BARREL)

Read More

http://covid19globalcases.com/novavax-coronavirus-vaccine-found-89-percent-efficient-in-trials/